Jack Childs

Co-founder & President

LSE BSc Economics

About Jack

I am President and Co-Founder of The London Review, where I lead a team of over 20 researchers and work across writing, editing and reviewing articles on economics, private markets, and public policy. I also built and maintain the website.

I founded The London Review to give ambitious student writers a place to get their work online and build a portfolio of high-quality, thorough analysis, rather than waiting until they have a job to be taken seriously. I am currently studying BSc Economics at LSE, with a particular interest in financial markets and the policy that steers them. Alongside my studies I have spent time this year at Compass Lexecon and on the Citi Summer Insight programme.

The work I am proudest of is our mentorship scheme, which I lead. It brings on sixth form students as Junior Researchers, giving them the chance to write seriously about a subject they care about and see their work published. Helping students find a subject they are genuinely passionate about, and giving them a foundation to take into university and their careers, is the part I value most.

Articles 29

  1. Student Spotlight

    The Economics of Climate Inaction

    Why do governments keep putting off climate action? The costs arrive long before the benefits, and public concern is not matching willingness to pay.

  2. Student Spotlight

    The AI Revolution: A Prisoner's Dilemma

    Fears over AI’s potential existential threat have entered the economic mainstream. As the US competes with China to lead the technology’s development, the prospect of slowing its advance looks increasingly remote.

  3. Markets

    The New Rules of Pharma M&A

    Big Pharma is acquiring earlier and accepting greater scientific risk for unproven drugs. The driver is not confidence in the science but the fear of a rival securing the next blockbuster first, as a $300bn patent cliff bears down on the industry.

  4. Markets

    AstraZeneca's Bet on the Future of COPD Treatment

    A $200 million upfront payment, with milestones potentially taking the deal's total value to $1.9 billion, gives AstraZeneca exclusive rights to develop and commercialise an experimental COPD treatment outside China. More importantly, it highlights a broader shift in how Big Pharma is sourcing innovation.

  5. Macro

    China's Exports Just Hit a Five-Year High, But the Economy Is Still Slowing

    China's factories are shipping more than they have in years, driven by an AI-fuelled tech boom. Yet second-quarter growth still slowed to 4.3%, its weakest in decades outside the pandemic, a reminder that strong exports don't always mean a strong economy.

  6. Markets

    Who Should Profit from Britain's Autism Crisis?

    As NHS waiting lists for autism assessments pass 200,000, private capital is flowing into neurodiversity services – forcing the question of whether profit and patient care can ever be aligned.

  7. Markets

    Has the FDA Just Revived Gene Therapy?

    A single FDA reversal sent Regenxbio's shares soaring and reignited optimism across gene therapy - but one favourable decision cannot solve the commercial challenges that pushed the industry into crisis.

  8. Markets

    What is happening with Asda?

    Five years after TDR Capital and the Issa brothers' £6.8bn leveraged buyout, Asda has posted a £989mn loss and seen its UK grocery market share fall to a record low. The question is whether the private equity playbook is compatible with running a thin-margin grocer in one of the world's most competitive retail markets.

  9. Markets

    Why Sycamore Walked Away from the London Float

    Boots looked like a deal story, but choosing a $10bn sale over a London float is really a verdict on the IPO: when a listing can't promise a price or a date, certainty wins.

  10. Markets

    The Data Moat: Why Google's Monopoly Is So Hard to Break

    A federal court ruled Google's search dominance is illegal. The remedies are an attempt to dismantle a monopoly built on data, defaults, and self-reinforcing scale. Whether they can work is an open question.

  11. Markets

    The Wall Street Bet on a $5,900 Ticket

    A Connecticut credit firm is lending millions against World Cup resale tickets, betting the markup holds. The trade exposes a wider story about how Wall Street is learning to finance scarcity.

  12. Macro

    The War America Can't Afford

    The war in Iran is testing the informal bargain that has let America borrow cheaply for half a century. The allies whose cooperation sustains that privilege had no say in the conflict, yet they are bearing its economic cost.

  13. Private Markets

    Week in Review: Private Capital & Dealmaking

    From Blackstone's bid for Senior plc to the largest LBO in history and a regulatory clash threatening the private credit ratings ecosystem, this week laid bare the tensions running through global private capital markets.

  14. Markets

    The Week That Reset the Rate Narrative

    Six central bank holds in 48 hours, Brent crude approaching $96, and a US-Iran military conflict have shattered the consensus rate narrative of early 2026, resetting the dollar, the yen, and the entire FX outlook.

  15. Markets

    The $3.8 Trillion Logjam

    Record unsold assets, zombie funds, and pension pain. Why the private equity industry is at a structural turning point.

  16. Markets

    Wall Street's Blind Spot

    Retail investors are pulling billions, insiders say defaults are already here, and banks are quietly tightening credit. The mixed signals across private credit mask a single uncomfortable truth.